Granted Patent B2

US 12,291,797 · App. 17/932,117 · Granted May 6, 2025

Inventors: Steven Jacobs (North Wales, PA); Karyn O'Neil (Media, PA)

Assignee: Janssen Biotech, Inc.

C40B40/10C07K14/78C40B40/08C40B50/06

Abstract

Claims (10)

1. An isolated protein scaffold based on a fibronectin type III (FN3) domain comprising:

a backbone portion having an amino acid sequence identical to SEQ ID NO:16 at residues 1-21, 29-74, and 82-89;

a B:C loop portion between residues 21 and 29 of SEQ ID NO:16 having at least 75% identity to any one of SEQ ID NOS:21-45; and

an F:G loop portion between residues 74 and 82 of SEQ ID NO:16 having at least 75% identity to any one of SEQ ID NOS:46-140, wherein the protein scaffold is capable of binding to human IgG.

2. The protein scaffold of claim 1 , comprising:

a backbone portion having an amino acid sequence identical to SEQ ID NO:16 at residues 1-21, 29-74, and 82-89;

a B:C loop portion between residues 21 and 29 of SEQ ID NO:16 comprising any one of SEQ ID NOS:21-45; and

an F:G loop portion between residues 74 and 82 of SEQ ID NO:16 comprising any one of SEQ ID NOS:46-140, wherein the protein scaffold is capable of binding to human IgG.

3. The protein scaffold of claim 1 , wherein said scaffold binds a target with at least one affinity selected from a K D of less than or equal to 10 −9 M, less than or equal to 10 −10 M, less than or equal to 10 −11 M, less than or equal to 10 −12 M, less than or equal to 10 −13 M, less than or equal to 10 −14 M, and less than or equal to 10 −15 M, as determined by surface plasmon resonance or the Kinexa method.

4. The protein scaffold of claim 2 , wherein the loops form sites for binding to IgG.

Assignments (2)

Continuity (7)

References Cited (96)